Trials / Terminated

TerminatedNCT01318421

A Study of ELND002 in Patients With Relapsing Forms of Multiple Sclerosis

An Open-Label, Long-Term, Follow-Up Study of Subcutaneous ELND002 in Patients With Relapsing Forms of Multiple Sclerosis

Status: Terminated
Phase: Phase 1
Study type: Interventional
Enrollment: 12 (actual)

Sponsor: Elan Pharmaceuticals · Industry
Sex: All
Age: 18 Years – 65 Years
Healthy volunteers: Not accepted

Summary

The purpose of this study is to evaluate the long-term safety and tolerability of ELND002 in patients with multiple sclerosis (MS) after participation in study MS103.

Conditions

Multiple Sclerosis

Interventions

Type	Name	Description
DRUG	ELND002

Timeline

Start date: 2010-12-01
Primary completion: 2012-12-01
First posted: 2011-03-18
Last updated: 2015-12-14

Source: ClinicalTrials.gov record NCT01318421. Inclusion in this directory is not an endorsement.